APASL 2023 Taiwan Congress Report
Catch up on the highlights of APASL 2023 with this congress report, covering session on hepatitis B, hepatitis C, hepatocellular carcinoma, and fatty liver disease.
READ MOREYou are about to leave the Clinical Value website now.
Catch up on the highlights of APASL 2023 with this congress report, covering session on hepatitis B, hepatitis C, hepatocellular carcinoma, and fatty liver disease.
READ MOREThis study was designed to investigate the potential role of PIVKA-II as a diagnostic, non-invasive marker for HCC at its early stages and to assess its…
READ MOREIn this Q&A, Prof Pierce Chow of the National Cancer Centre Singapore discusses the epidemiology of liver disease in Asia Pacific; key considerations around the clinical…
READ MOREPunjab is one of Pakistan’s largest provinces and has a particularly high HCV prevalence rate of roughly 9%, compared to 5.4% for Pakistan’s total population. Hear…
READ MOREIn 2019, Pakistan announced a nationwide programme to scale up HCV prevention, testing and treatment. Hear from gastroenterologist Dr Huma Qureshi, a key figure in Pakistan’s…
READ MOREAn estimated 71 million people around the world are chronically infected with hepatitis C virus (HCV), with a large proportion currently being undiagnosed or diagnosed late.…
READ MOREIn 2018, the world’s largest HCV screening campaign was initiated in Egypt. Within 7 months following its initiation, 49.5 million people were screened; and 2.2 million…
READ MOREThe province of Sindh has one of the world’s highest rates of HCV infection and bears the second highest disease burden of both HBV and HCV…
READ MOREPakistan has one of the world’s highest rates of HCV infection. Learn from Dr Zaigham Abbas, Head of Gastroenterology at Ziauddin University Hospital and President of…
READ MOREPakistan has one of the world’s highest rates of HCV infection. It's no surprise that their healthcare systems face mounting pressure from HCV-related conditions. Learn from…
READ MORE